167 related articles for article (PubMed ID: 33630144)
1. Progression of gastrointestinal symptoms over time in patients with systemic sclerosis.
Bering J; Griffing WL; Crowell M; Umar SB
Rheumatol Int; 2021 Jul; 41(7):1281-1287. PubMed ID: 33630144
[TBL] [Abstract][Full Text] [Related]
2. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
[TBL] [Abstract][Full Text] [Related]
3. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
[TBL] [Abstract][Full Text] [Related]
4. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
[TBL] [Abstract][Full Text] [Related]
6. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
McMahan ZH; Frech T; Berrocal V; Lim D; Bruni C; Matucci-Cerinic M; Smith V; Melsens K; Proudman S; Zhang J; Mendoza F; Woods M; Khanna D
J Rheumatol; 2019 Jan; 46(1):78-84. PubMed ID: 30442827
[TBL] [Abstract][Full Text] [Related]
8. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
[TBL] [Abstract][Full Text] [Related]
9. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Zekovic A; Damjanov N
Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
[TBL] [Abstract][Full Text] [Related]
10. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
[TBL] [Abstract][Full Text] [Related]
12. A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis.
Maclean RH; Ahmed F; Ong VH; Murray CD; Denton CP
J Rheumatol; 2023 Jul; 50(7):907-915. PubMed ID: 36792109
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.
McMahan ZH; Tucker AE; Perin J; Volkmann ER; Kulkarni S; Ziessman HA; Pasricha PJ; Wigley FM
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):442-450. PubMed ID: 33064934
[TBL] [Abstract][Full Text] [Related]
14. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
Luebker S; Frech TM; Assassi S; Gordon JK; Bernstein EJ; Steen VD; Shah AA; Hummers LK; Richardson C; Khanna D; Castelino FV; Chung L; Hant FN; Shanmugam VK; VanBuren JM; Alvey J; Harding M; Sandorfi N
Clin Exp Rheumatol; 2023 Aug; 41(8):1632-1638. PubMed ID: 37497718
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal involvement in patients with systemic sclerosis.
Wielosz E; Borys O; Zychowska I; Majdan M
Pol Arch Med Wewn; 2010 Apr; 120(4):132-6. PubMed ID: 20424538
[TBL] [Abstract][Full Text] [Related]
16. Nutritional status and gastrointestinal symptoms in systemic sclerosis patients.
Murtaugh MA; Frech TM
Clin Nutr; 2013 Feb; 32(1):130-5. PubMed ID: 22770637
[TBL] [Abstract][Full Text] [Related]
17. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
18. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.
Thoua NM; Bunce C; Brough G; Forbes A; Emmanuel AV; Denton CP
Rheumatology (Oxford); 2010 Sep; 49(9):1770-5. PubMed ID: 20530510
[TBL] [Abstract][Full Text] [Related]
19. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis.
Omair MA; Lee P
J Rheumatol; 2012 May; 39(5):992-6. PubMed ID: 22467930
[TBL] [Abstract][Full Text] [Related]
20. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
